Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

1993-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

OBJECTIVES: I. Correlate clinical outcome with cerebral glucose metabolism in patients with Huntington's disease (HD) and their at-risk relatives.

II. Evaluate the efficacy of cerebral glucose metabolism in observing the pathophysiologic development of HD, monitoring responses to experimental therapy, and predicting HD genotype.

III. Identify, define, and describe the natural history of pathophysiologic lesions in HD.

IV. Characterize the genotypic and phenotypic expression of the HD gene.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PROTOCOL OUTLINE: Participants are screened for Huntington's disease, including cerebral glucose metabolism assessment and genetic testing.

Studies include a detailed family history and neurologic, psychometric, and neurobehavioral evaluations. Imaging includes positron emission tomography with fluorodeoxyglucose and brain magnetic resonance imaging.

A genotype assessment is performed; genetic results are not disclosed to patients or relatives.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Huntington's Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Huntington's disease neurologic and psychiatric disorders rare disease

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

* Documented family history of Huntington's disease (HD)
* Symptomatic HD: chorea required
* At-risk for HD: no detectable systemic or oculomotor abnormality
* Age-matched control subjects
* No history of inherited neurological disease
* No general or neurologic abnormality

--Prior/Concurrent Therapy--

At least 4 weeks since other HD treatment, e.g.:

* Haloperidol
* Benzodiazepine
* Other tranquilizers or neuroleptics

--Patient Characteristics--

* No pregnant women

Minimum Eligible Age

0 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John C. Mazziotta

Role: STUDY_CHAIR

University of California, Los Angeles

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UCLA-90063784

Identifier Type: -

Identifier Source: secondary_id

199/11677